M ultidrug resistance proteins (MRPs) are members of the ATP-binding cassette family and originally were identified as mediators of chemoresistance in cancer cells. MRPs are active transporters for a variety of endogenously produced and exogenously administered molecules, including chemotherapeutic agents. 1 Presently, MRP1 is the best-investigated member of this protein family. MRP1 acts as transporter for substances such as glutathione, oxidized glutathione, estrogen, and leukotriene C 4 (LTC 4 ), 2, 3 which are all potentially important for the regulation of reactive oxygen species (ROS) production in vascular cells. We have recently shown that MRP1 is expressed in human aortic endothelial cells and that modulation of MRP1 expression affects vascular function. 4 MRP1 blockade or depletion stabilized the intracellular redox potential, decreased ROS-induced endothelial cell apoptosis, and improved vascular function in mice with desoxycorticosterone acetate (DOCA) salt-induced hypertension. 4 Furthermore, it has been shown that hypertension caused by angiotensin (Ang) II is markedly reduced in MRP1 Ϫ/Ϫ mice compared with wild-type mice. 5 
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So far, the underlying intracellular mechanisms of the reported effects remain unclear. An increased turnover rate of the glutathione redox system has been discussed as the most important effect of MRP1 depletion/blockade. 2, 3 Glutathione is one of the most abundant thiol antioxidants in cells. It is involved in cellular division, protein and DNA synthesis, maintenance of cellular redox homeostasis, and regulation of apoptosis. Catalyzed by the enzyme glutathione peroxidase, glutathione can be easily converted to its oxidized form (GSSG). GSSG in turn can be either exported out of the cytoplasm via MRP1 or regenerated to glutathione by the enzyme glutathione reductase. 5 Either accumulation or increased export of GSSG leads to cellular apoptosis. We have recently demonstrated that MRP1 blockade reduces oxidative stress by increasing the activity of the glutathione reductase in human aortic endothelial cells. 3 However, this moderate upregulation may only partially explain the observed vasoprotective effects in an in vivo situation. Therefore, we hypothesized that additional intracellular mechanisms contribute to the atheroprotective effects of MRP1 blockade or depletion.
LTC 4 , the conjugation product of glutathione and leukotriene A 4 , is a mediator of inflammation, increases postcapillary permeability, causes vasoconstriction, and induces oxidative stress. 6 LTC 4 is metabolized in vascular smooth muscle cells (VSMCs), macrophages, and leukocytes. 6, 7 In VSMCs, LTC 4 release can be triggered by Ang II. 8 LTC 4 mediates its biological effects by binding to the Cys-LT1 receptor. Because the Cys-LT1 receptor is located on the cellular membrane of VSMCs, transport of LTC 4 from the intracellular to the extracellular compartment is necessary to promote LTC 4 effects via its receptor. It has been shown that LTC 4 displays a high affinity to MRP1. Thus, we hypothesize that MRP1 could be important for atherogenesis and that inside-outside transport of LTC 4 could resemble a relevant mechanism.
Methods

Materials
Antibodies for Western blotting were purchased from Kamiya Biomedical (Seattle, Wash). All other materials necessary for Western blotting were acquired from Bio-Rad Laboratories (Hercules, Calif). MK571 and the caspase 3 colorimetric assay were obtained from Alexis Biochemicals (San Diego, Calif). DCF (2Ј,7Ј-dichlorofluorescin), Ang II, and LTC 4 were purchased from Sigma (St Louis, Mo). Montelukast (Singulair) was obtained from MSD (Haar, Germany). The LTC 4 measurements were performed with Amersham's B 4 /C 4 /E 4 leukotriene detection assay (Uppsala, Sweden). Reverse transcription of RNA was performed with the SuperScript III kit (Invitrogen, Carlsbad, Calif).
Cell Culture
Confluent VSMCs of either rat or mouse origin were used. Cells were prepared as published previously. 9 Rat VSMCs were isolated from rat thoracic aorta (strain, male Sprague-Dawley; age, 6 to 10 weeks old; Charles River GmbH, Sulzfeld, Germany); mouse VSMCs were isolated from mouse thoracic aortas of male FVB and male MRP1 Ϫ/Ϫ mice purchased from Taconic Animal Models (Germantown, NY). Passages 3 through 10 were used for the experiments performed. Cell culture media and materials were obtained from Gibco (Carlsbad, Calif).
Detection of MRP1 mRNA and Protein
MRP1 mRNA and protein were detected by polymerase chain reaction and Western blotting according to protocols published previously. 3 
Western Analysis
To detect MRP1 in mouse VSMCs, we used the monoclonal antibody MRPr1 (Kamiya) at a dilution of 1:100. Actin immunoblotting was used to normalize for loading variations.
Polymerase Chain Reaction
Total RNA (3 g) was reverse transcribed using random primers and a SuperScript III kit (Invitrogen). DNA was amplified with the following primers for MRP1 (forward, 5Ј-CAGAGCAGGAGCAGGATGCAGAGGA-3Ј; reverse, 5Ј-GGA-ACCAGCGCGCGGÁCACATGGT-3Ј).
Determination of ROS production
Intracellular ROS production in VSMCs was measured by L012 fluorescence as described previously. 10 To perform these measurements, VSMCs were cultivated in 96-well plates until they reached confluence. The cells were then stimulated for up to 12 hours with the different substances indicated in the Results section. Cells were then harvested (trypsin) and resuspended in equal volumes of Krebs-HEPES-buffer with 100 mol/L L012. Chemiluminescence was assessed after an incubation for 5 minutes over a time course of 15 minutes in a scintillation counter (Lumat LB 9501, Berthold, Bad Wildbad, Germany) in 1-minute intervals.
Determination of LTC 4 Release of VSMCs
For determination of LTC 4 release in cell culture supernatant of VSMCs, the leukotriene C 4 /D 4 /E 4 Biotrak assay (Amersham) was used. VSMCs were cultured in a 96-well plate until they reached confluence. The cells were then incubated with the different substances (eg, MK571/montelukast) for 12 hours as indicated in Results. Afterward, 200 L cell culture supernatant was collected and added to the 96-well plate provided with the kit for 2 hours. The following steps were performed according to the manufacturer's protocol.
Animal Experiments
Twelve-week-old apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mice were fed a Western diet for 6 weeks. The animals were treated with either MK571, a pharmacological antagonist of MRP1 (5 mg · kg
. Placebo-treated animals served as the control group. The mice were killed, and the aortas were excised. The vessel was then immersed in chilled buffer containing (in mmol/L) NaCl 118.0, CaCl 2 2.5, KCl 4.73, MgCl 2 1.2, KH 2 PO 4 1.2, NaHCO 3 25.0, NaEDTA 0.026, and D(ϩ)glucose 5.5, pH 7.4. Perivascular adipose tissue was carefully removed. Rings (3 mm) were mounted in organ chamber baths filled with the described buffer (37°C, continuously aerated with 95% O 2 and 5% CO 2 ) and attached to a force transducer, and isometric tension was recorded. The vessels were gradually stretched over 60 minutes to a resting tension of 10 mN, which was maintained throughout the experiment, and were allowed to equilibrate for another 30 minutes. Drugs were added in increasing concentrations to obtain cumulative concentration-response curves: KCl 20 and 40 mmol/L, Ang II 1 nmol/L to 1 mol/L, phenylephrine 1 nmol/L to 10 mol/L, carbachol 10 nmol/L to 100 mol/L, and nitroglycerin 1 nmol/L to 10 mol/L. The drug concentration was increased when vasoconstriction or relaxation was completed. Drugs were washed out before the next substance was added. Atherosclerotic lesion development was determined as published previously. Sections of the aortic root were embedded in Tissue Tek optical coherence tomography embedding medium, snap-frozen, and stored at Ϫ80°C. Samples were sectioned on a Leica cryostat and placed on poly-L-lysine-coated slides for analysis. Sections of the aortic root were then stained with Oil Red O and analyzed with software measuring the atherosclerotic lesion area in relation to the lumen of the vessel.
Statistical Analysis
Values are expressed as meanϮSEM and were compared between groups by use of ANOVA. The Student-Newman-Keuls post hoc test was performed when significance is indicated. For comparisons between 2 groups, Student's t test was used.
All authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Pharmacological MRP1 Inhibition Decreases Ang II-Induced ROS Release
We assessed the expression of MRP1 in cultured VSMCs by Western blotting and reverse-transcription polymerase chain reaction and found a strong expression of MRP1. This expression was not altered by Ang II stimulation for up to 16 hours (data not shown). In a following experiment, we investigated whether pharmacological inhibition of MRP1 affected the Ang II-induced ROS generation. VSMCs were grown to confluence and incubated with either Ang II (10 Ϫ6 mol/L) or the pharmacological MRP1 inhibitor MK571 (5 mol/L) or coincubated with both substances. After 12 hours of incubation, the generation of ROS was determined by L012 fluorescence ( Figure 1A ). MK571 significantly diminished the ROS generation in VSMCs after coincubation with Ang II by 59Ϯ5%. To rule out side effects of the pharmacological inhibitor, we performed a similar experiment using MRP1 Ϫ/Ϫ cells ( Figure 1B) . Stimulation with Ang II resulted in a significantly diminished generation of ROS in MRP1
VSMCs by 79Ϯ9% compared with wild-type VSMCs. These findings indicate an important role of MRP1 in Ang IIinduced ROS production in VSMCs.
Ang II Causes LTC 4 Release in VSMCs
We wondered whether MRP1-associated ROS generation was connected to LTC 4 LTC 4 increased ROS production, whereas stimulation with Ang II showed no effect. Incubation with Montelukast and coincubation with Montelukast and LTC 4 did not alter the ROS level in MRP1 Ϫ/Ϫ VSMCs.
Pharmacological MRP1 Inhibition and Cys-LT1 Receptor Blockade Affect ROS Production, Endothelial Function, and Atherogenesis in ApoE ؊/؊ Mice In Vivo
To extend our findings to the in vivo setting, 3-month-old atherosclerosis-prone ApoE Ϫ/Ϫ mice receiving a cholesterol-enriched diet for 6 weeks were treated with MK571 (5 mg · kg
, or placebo. All mice were fed a high-fat, cholesterol-rich diet containing 21% fat, 19.5% casein, and 1.25% cholesterol.
The animals were then killed, aortas were excised, and endothelial function was analyzed in organ chamber experiments. Pharmacological inhibition of MRP1 and Cys-LT1 receptor inhibition reduced ROS production (L012 chemiluminescence) by 55Ϯ10% and resulted in a significantly improved endothelial function compared with placebo-treated controls (Figure 4 ). Endothelium-independent relaxation (nitroglycerin) remained unchanged. Application of MK571 or montelukast improved endothelial function to almost identical extents. Furthermore, we analyzed the development of atherosclerotic lesions in the aortic sinus ( Figure 5 ). Treatment with MK571 diminished the size of atherosclerotic plaques (Oil Red O staining) by 52Ϯ11%. Treatment with montelukast showed a similar effect, with a reduction of 61Ϯ10%.
Discussion
Here, we show that MRP1 is expressed in VSMCs and acts as a transport protein for LTC 4 . Inhibition of MRP1 reduces inside-outside transport of LTC 4 , causing reduced ROS production. Furthermore, both inhibition and blockade of the Cys-LT1 receptor decrease ROS production, improve endothelial function, and ameliorate atherogenesis in vivo. These findings support prior publications showing a beneficial role of MRP1 inhibition in DOCA salt-hypertensive mice and in mice with Ang II-induced hypertension. 3, 4 Although the major scientific interest in MRP1 was focused on its role in mediating resistance to anticancer drugs in tumor cells, 11 there is now growing evidence that MRP1 also plays an important role in vascular function and in the setting of oxidative stress. Most of the chemotherapeutic agents transported via MRP1 require coupling to glutathione to be transported. In fact, glutathione is one of the substrates with the highest affinity to the MRP1 protein. 1 The idea that MRP1 might affect the management of oxidative stress was groundbreaking when Hirrlinger et al 2 discovered that oxidative stress causes the release of glutathione via MRP1 in astrocytes. Later, it was reported that in addition to the reduced form of glutathione, its oxidized form (GSSG) can be transported via MRP1. The glutathione redox system belongs to the basic antioxidative systems in almost every cell type. 5 It enables cells to cope with oxidative stress and almost exclusively determines the intracellular redox potential in human aortic endothelial cells. Given the importance of this system, we focused in prior studies mainly on the effects of MRP1 inhibition on the glutathione redox system. Oxidative stress results in human aortic endothelial cells in extrusion of GSSG and finally in glutathione depletion, which is one of the strongest triggers of apoptosis and cellular death. 12 On the other hand, accumulation of GSSG also can trigger apoptosis. It was therefore surprising that MRP1 inhibition led in human aortic endothelial cells to improved cellular survival. Obviously, uncontrolled GSSG accumulation did not occur. We discovered that MRP1 inhibition upregulated the activity of the enzyme glutathione reductase, one of the key enzymes of the glutathione redox system, catalyzing the reduction of GSSG back to glutathione. However, this increase was only moderate (40%) and only partially explained the beneficial effects of MRP1 inhibition. 3 In the same study, we analyzed the expression of MRP1 in the vascular wall of DOCA salt-hypertensive mice and found it expressed at a remarkable level.
VSMCs present the majority of cells within the vascular wall. Therefore, a relevant expression of MRP1 in VSMCs was a likely finding. It was also likely that the glutathione redox system would be less important in VSMCs because these cells are less exposed to sudden oxidative stress and show different coping mechanisms and physiological reactions like the induction of cellular growth when exposed to ROS. One major trigger of ROS generation in VSMCs is Ang II. 13 Widder et al 4 investigated the effect of Ang II infusion in MRP1 Ϫ/Ϫ mice and reported a variety of effects connected with MRP1 in respect to vascular function. Among them are a lower blood pressure, reduced production of ROS, and better endothelial function in MRP1
Ϫ/Ϫ animals compared with control mice. We hypothesized that besides the already reported effects of MRP1 inhibition on the glutathione/GSSG system, alternative mechanisms should contribute to the observed effects in VSMCs. Among the substrates with high affinity for MRP1 is LTC 4 . LTC 4 mediates inflammatory reactions in respiratory tissue, and it is instrumental in the pathogenesis and treatment of asthma. 14 In respiratory tissue, LTC 4 induces ROS production via EGF receptor transactivation and ERK1/2 phosphorylation. 15 A potential connection between MRP1 and LTC 4 was supported by observations in MRP1 Ϫ/Ϫ mice showing an insusceptibility of MRP1 Ϫ/Ϫ mice to infection with pneumococci combined with dramatically improved survival. 16 The major source of LTC 4 in human tissue is leukocytes, but LTC 4 also can be generated and released by VSMCs. 8 It was therefore reasonable to assume that at least part of the observed antiatherosclerotic effects could be based on reduced generation and release of LTC 4 by VSMCs. Especially in early stages of atherosclerotic lesion development, this VSMC-driven LTC 4 release might be of importance. In advanced stages, the major source of LTC 4 is most likely macrophages. In our experimental setting, Ang II stimulation of VSMCs resulted in an increased LTC 4 release. This finding is in accordance with the results of Luchtefeld et al, 17 who demonstrated that Ang II enhances leukotriene formation in VSMCs via induction of the lipoxygenase 5. Leukotriene formation resulted in an increased ROS production. The study presented here demonstrates that Ang II induces intracellular ROS formation via induction of LTC 4 , which is transported to . Afterward, the animals were killed, the aortas were excised, and endothelial function was determined. Pharmacological inhibition of MRP1 and the Cys-LT1 receptor resulted in significantly improved endothelial function compared with placebo-treated controls. Endothelium-independent relaxation (nitroglycerin) remained unchanged (nϭ5; PϽ0.05).
